ReviewJournal of immunology research2022
Cytokines in Thyroid-Associated Ophthalmopathy.
Review in Journal of immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Association of IL-6 and IL-17 with thyroid eye disease.Frontiers in endocrinology · 2026Pooled it
- Optical coherence tomography angiography in thyroid associated ophthalmopathy: a systematic review.BMC ophthalmology · 2024Pooled it
- Serum free fatty acid profiles as novel biomarkers for disease activity in Graves' orbitopathy.Journal of endocrinological investigation · 2026Article
- TNFα drives disease-specific chemokine networks and orbital tissue remodeling in a preclinical model of thyroid eye disease.European thyroid journal · 2026Article
- Association Between Peripheral IL-2Journal of clinical medicine · 2026Article
- Elevated blood viscosity in thyroid-associated ophthalmopathy and its association with thyroid-stimulating immunoglobulin levels.Scientific reports · 2026Article
- The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease.Reviews in endocrine & metabolic disorders · 2026Review
- Article
- Effectiveness of 0.05% cyclosporine A eye drops for dry eye disease in patients with thyroid-associated ophthalmopathy: a prospective, parallel-group cohort study.Frontiers in medicine · 2026Article
- Cytokines and drugs targeting cytokines in Graves' disease and thyroid eye disease.Frontiers in immunology · 2026Review
- Contiguous orbital inflammation from paranasal sinus abnormalities in etiology of thyroid-associated ophthalmopathy.International journal of ophthalmology · 2026Article
- Danshenol A Mediates the Proliferation and Differentiation of Adipocytes in Thyroid-Associated OphthalmopathyEndocrine, metabolic & immune disorders drug targets · 2026Article
- Clinical predictors of tocilizumab response in moderate-to-severe thyroid eye disease: a large single-center retrospective cohort study.Frontiers in endocrinology · 2026Article
- Interleukin-27 is a multitarget regulator of fibroblast remodeling in thyroid-associated ophthalmopathy.iScience · 2025Article
- Investigation of the molecular mechanism of Xiaoluo Wan in thyroid-associated ophthalmopathy: network analysis and in vivo study.Hereditas · 2025Article
- Orbital Clinicopathological Differences in Thyroid Eye Disease: An Analysis of Cytokines With Histopathological and Clinical Correlation.Investigative ophthalmology & visual science · 2025Article
- Extraocular muscle index as a novel indicator of inflammatory condition in graves' ophthalmopathy patients.Frontiers in endocrinology · 2025Observational
- IL-17 and IL-38 gene polymorphisms in thyroid-associated ophthalmopathy.International ophthalmology · 2024Article
- Thyroid-associated ophthalmopathy and ferroptosis: a review of pathological mechanisms and therapeutic strategies.Frontiers in immunology · 2024Review
- Hyperlipidemia and apolipoprotein E are associated with intraocular pressure of thyroid-associated ophthalmopathy in a Chinese population: a cross-sectional study.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' orbitopathy (GO), is a complex autoimmune condition causing visual impairment, disfigurement, and harm to patients' physical and mental health. The pathogenesis of TAO has not been fully elucidated, and the mainstream view is that coantigens shared by the thyroid and orbit trigger remodeling of extraocular muscles and orbital connective tissues through an inflammatory response. In recent years, cytokines and the immune responses they mediate have been crucial in disease progression, and currently, common evidence has shown that drugs targeting cytokines, such as tocilizumab, infliximab, and adalimumab, may be novel targets for therapy. In this review, we summarize the research development of different cytokines in TAO pathogenesis in the hope of discovering new therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.